retatrutide eli lilly press release 2024 2025 Lilly's triple-acting obesity drug hits goal in Phase 3 trial Lilly's triple agonist achieves 16.8%
Description
What are GLP-1 and GIP
A direct head-to-head trial (NCT06662383, 800 patients) is underway with results in December 2026
There were people who didnt want to see their stock price go down if something went wrong
Ive never looked back
Does Ambetter cover Ozempic
Were not providing individual or group medical or healthcare advice, or establishing a provider-patient relationship
